» Articles » PMID: 9820843

Subclinical Reactivation of Varicella-zoster Virus in Immunocompromised and Immunocompetent Individuals

Overview
Journal Intervirology
Specialty Microbiology
Date 1998 Nov 20
PMID 9820843
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The occurrence of subclinical reactivation of varicella-zoster virus (VZV) in peripheral blood mononuclear cells (PBMC) from immunocompetent subjects >60 years old without any signs of VZV-caused illnesses, and from immunocompromised patients was investigated. Altogether, 223 samples were tested by nested ORF 63 PCR assay. In addition, all positive samples were tested by ORF 14, ORF 29 and ORF 63 PCR assays, as well as by ORF 63 and ORF 68 nucleic acid sequence-based amplification assays. In 5 samples, VZV-specific DNA, but no transcripts, could be detected. Three of them belonged to the group of >60-year-olds, 1 was HIV positive, the other was being treated with chemotherapy. The results confirm the observation of other authors that subclinical reactivation occurs in both immunocompromised and healthy individuals. The failure to detect DNA in samples taken from 2 individuals several weeks later excludes a long-lasting infection of VZV in PBMC.

Citing Articles

Clinically- versus serologically-identified varicella: A hidden infection burden. A ten-year follow-up from a randomized study in varicella-endemic countries.

Gillard P, Povey M, Carryn S Hum Vaccin Immunother. 2021; 17(10):3747-3756.

PMID: 34181506 PMC: 8437481. DOI: 10.1080/21645515.2021.1932217.


Incidence of varicella and herpes zoster after inclusion of varicella vaccine in national immunization schedule in Turkey: time trend study.

Soysal A, Gonullu E, Yildiz I, Karabocuoglu M Hum Vaccin Immunother. 2020; 17(3):731-737.

PMID: 32703071 PMC: 7993137. DOI: 10.1080/21645515.2020.1788861.


The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting.

Sauboin C, Holl K, Bonanni P, Gershon A, Benninghoff B, Carryn S BMC Infect Dis. 2019; 19(1):126.

PMID: 30727971 PMC: 6366068. DOI: 10.1186/s12879-019-3759-z.


Immune responses to zoster vaccines.

Levin M, Weinberg A Hum Vaccin Immunother. 2019; 15(4):772-777.

PMID: 30676834 PMC: 6605864. DOI: 10.1080/21645515.2018.1560918.


Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine.

Perciani C, Jaoko W, Walmsley S, Farah B, Mahmud S, Ostrowski M BMJ Open. 2017; 7(9):e017391.

PMID: 28939581 PMC: 5623463. DOI: 10.1136/bmjopen-2017-017391.